SELLAS Announces First Patient Dosed In Phase Ib/II Trial Of SLS009 (GFH009) In Relapsed/Refractory Peripheral T-cell Lymphomas
Portfolio Pulse from Bill Haddad
SELLAS Life Sciences Group, Inc. has announced that the first patient has been dosed in a Phase Ib/II trial of SLS009 (GFH009) in relapsed/refractory peripheral T-cell lymphomas. This marks a significant step in the development of the drug.
October 11, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SELLAS Life Sciences has dosed the first patient in a Phase Ib/II trial of SLS009. This is a key milestone in the drug's development, potentially impacting the company's stock positively.
The dosing of the first patient in a clinical trial is a significant milestone in drug development. This news indicates progress in SELLAS's pipeline, which could positively impact investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100